Who
Brian Daniels
Director
Company insider
Files Form 4 as: Director, Artiva Biotherapeutics; Director, Cabaletta Bio; SVP Global Dev & Med Affairs, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 165
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $5.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 4 Mar 2008
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 1 Jun 2021filed 28 Jun 2021 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 1 Jun 2021filed 3 Jun 2021 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 11 Feb 2020filed 13 Feb 2020 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 1 Jul 2014filed 2 Jul 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —4,671 at $0.00 | filing |
| 1 Jul 2014filed 2 Jul 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $101K2,103 at $48.12 | filing |
| 1 Jul 2014filed 2 Jul 2014 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,671 at $0.00 | filing |
| 10 Mar 2014filed 12 Mar 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —2,528 at $0.00 | filing |
| 10 Mar 2014filed 12 Mar 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —1,147 at $0.00 | filing |
| 10 Mar 2014filed 12 Mar 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $93K1,655 at $56.14 | filing |
| 10 Mar 2014filed 12 Mar 2014 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,528 at $0.00 | filing |
| 10 Mar 2014filed 12 Mar 2014 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,741 at $0.00 | filing |
| 6 Mar 2014filed 10 Mar 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —3,010 at $0.00 | filing |
| 6 Mar 2014filed 10 Mar 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —2,044 at $0.00 | filing |
| 6 Mar 2014filed 10 Mar 2014 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $126K2,276 at $55.56 | filing |
| 6 Mar 2014filed 10 Mar 2014 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,010 at $0.00 | filing |
News
Thomas Built Buses Names Brian Daniels Vice President of Sales, Aftermarket and Marketingstnonline.com · 17 Sep 2026Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?BMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 VolatilityBMY · fool.com · 22 Oct 2026AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?BMY · fool.com · 21 Oct 2026
1 headline in the last 90 days name Brian Daniels; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.